Shares of Curis, Inc. (NASDAQ:CRIS) have received a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $6.67.
CRIS has been the subject of a number of research reports. Cowen and Company reiterated a “buy” rating on shares of Curis in a research report on Friday, May 5th. Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, BidaskClub lowered shares of Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th.
Shares of Curis (NASDAQ:CRIS) opened at 1.72 on Friday. The firm has a 50-day moving average of $1.93 and a 200 day moving average of $2.27. The firm’s market cap is $247.47 million. Curis has a 52 week low of $1.47 and a 52 week high of $3.72.
Curis (NASDAQ:CRIS) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. Curis’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) EPS. Equities research analysts predict that Curis will post ($0.40) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/12/curis-inc-cris-receives-average-rating-of-hold-from-brokerages.html.
Institutional investors have recently modified their holdings of the company. State Street Corp raised its position in shares of Curis by 5.5% in the fourth quarter. State Street Corp now owns 1,663,980 shares of the biotechnology company’s stock worth $5,125,000 after buying an additional 86,308 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Curis by 152.0% in the fourth quarter. Renaissance Technologies LLC now owns 361,100 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 217,800 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Curis by 7.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 82,518 shares of the biotechnology company’s stock worth $254,000 after buying an additional 5,585 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Curis by 62.5% in the fourth quarter. Teachers Advisors LLC now owns 368,278 shares of the biotechnology company’s stock worth $1,134,000 after buying an additional 141,712 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in shares of Curis by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock worth $344,000 after buying an additional 12,344 shares during the last quarter. Hedge funds and other institutional investors own 51.67% of the company’s stock.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
What are top analysts saying about Curis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Curis Inc. and related companies.